Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 198 entries
View as:

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Phase: N/A Priority: Normal
NCT ID: NCT05335473 Org: User:
Start: 05/13/22 End: 11/01/25 Due: 11/01/26

Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain

Phase: N/A Priority: Normal
NCT ID: NCT05962294 Org: User:
Start: 06/01/23 End: 07/31/24 Due: 07/31/25

An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06436885 Org: User:
Start: 02/28/24 End: 12/31/25 Due: 12/31/26

ARX788 in HER2-positive Metastatic Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06663748 Org: User:
Start: 11/20/24 End: 11/20/29 Due: 11/20/30

The Application of 3T MRI in Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03635619 Org: User:
Start: 09/02/18 End: 12/30/23 Due: 12/30/24

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03985670 Org: User:
Start: 07/10/19 End: 04/30/23 Due: 04/30/24

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Phase: N/A Priority: Normal
NCT ID: NCT05608785 Org: User:
Start: 01/01/23 End: 10/01/24 Due: 10/01/25

Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03983759 Org: User:
Start: 06/20/19 End: 05/31/21 Due: 05/31/22

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Phase: N/A Priority: Normal
NCT ID: NCT06334757 Org: User:
Start: 05/08/23 End: 06/30/25 Due: 06/30/26

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06406673 Org: User:
Start: 10/16/23 End: 12/31/24 Due: 12/31/25

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Phase: N/A Priority: Normal
NCT ID: NCT04063683 Org: User:
Start: 10/07/19 End: 06/30/22 Due: 06/30/23

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Phase: N/A Priority: Normal
NCT ID: NCT02924753 Org: User:
Start: 07/18/16 End: 12/31/19 Due: 12/31/20

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05299255 Org: User:
Start: 09/05/21 End: 09/05/23 Due: 09/05/24

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06781281 Org: User:
Start: 12/04/24 End: 11/28/30 Due: 11/28/31

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05911958 Org: User:
Start: 07/05/23 End: 05/31/29 Due: 05/31/30

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05063136 Org: User:
Start: 09/28/21 End: 09/30/28 Due: 09/30/29

Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03413436 Org: User:
Start: 01/31/18 End: 02/21/18 Due: 02/21/19

An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04087252 Org: User:
Start: 09/04/19 End: 12/30/21 Due: 12/30/22

Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT05598827 Org: User:
Start: 12/28/24 End: 12/31/25 Due: 12/31/26

Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)

Phase: N/A Priority: Normal
NCT ID: NCT05359120 Org: User:
Start: 05/30/22 End: 05/31/24 Due: 05/31/25

Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04199559 Org: User:
Start: 12/01/19 End: 01/01/22 Due: 01/01/23

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05640713 Org: User:
Start: 12/01/22 End: 08/01/25 Due: 08/01/26

Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05569668 Org: User:
Start: 01/01/21 End: 08/01/22 Due: 08/01/23

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04891900 Org: User:
Start: 05/10/21 End: 12/01/24 Due: 12/01/25

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

Phase: N/A Priority: Normal
NCT ID: NCT04778800 Org: User:
Start: 03/20/21 End: 02/20/24 Due: 02/20/25